Anticancer Effects of New Disulfiram Analogs

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Disulfiram (DSF), an FDA-approved alcoholism drug, exhibits antitumor properties but causes side effects due to aldehyde dehydrogenase 2 (ALDH2) inhibition.
• Developing DSF analogs with reduced ALDH2 inhibition is crucial for safer anticancer therapies.

Purpose of the Study:

• To evaluate the anticancer activity of novel DSF analogs with limited ALDH2 inhibition.
• To investigate the effects of these analogs on cell signaling pathways in Jurkat cells.

Main Methods:

• Synthesis of DSF analogs (2a-v).
• Assessment of anticancer activity and apoptosis induction in Jurkat cells.
• Differential gene expression analysis to understand pathway modulation.

Main Results:

• DSF analogs 2g and 2r demonstrated significant anticancer effects, inducing higher levels of apoptosis than DSF.
• Compounds 2g and 2r modulated cell signaling by downregulating growth pathways and upregulating apoptosis and differentiation pathways.
• Both analogs triggered more DNA damage-related gene expression changes compared to DSF, suggesting a distinct mechanism of action.

Conclusions:

• DSF analogs 2g and 2r possess potent anticancer activity and induce apoptosis and DNA damage with potentially fewer side effects than DSF.
• These novel compounds represent promising candidates for further development as anticancer agents.